|
|
||||||||
European Journal of Cardio-Thoracic Surgery, Vol 9, 305-309, Copyright © 1995 by European Association for Cardio-thoracic Surgery
P Ciriaco, EA Rendina, F Venuta, T De Giacomo, G Della Rocca, I Flaishman, C Baroni, E Cortesi, G Bonsignore and C Ricci
From January 1991 to November 1993, 110 patients with histologically
confirmed stage IIIA and IIIB non-small cell lung cancer (NSCLC), were seen
at our Institution. Our study was designed to evaluate whether redirection
to surgery of otherwise unresectable patients may be obtained by
preoperative therapy. Forty-nine patients were considered eligible for
neoadjuvant treatment. Thirty-two (Group I) were treated with two or three
cycles of cisplatin, vinblastine and mitomycin C and 17 (Group II) received
two cycles of cisplatin, VP16, alpha 1 timosine and interferon. The overall
response rate was 81.2% for Group I and 88.7% for Group II. Downstaging was
predictive of resectability (P < 0.05). Forty-one patients (83.6%)
underwent thoracotomy with 37 (75.5%) radical resections. Conservative
techniques (bronchovascular reconstruction) (22 cases) were preferred over
pneumonectomy (2 cases). The resectability rate was 84% for Group I and 87%
for Group II (P = NS). Treatment-related complications were minor, with no
deaths. Postoperative complications occurred in two cases in each group
(7.4% and 14.3%). There was no histologic evidence of tumor in three
patients. Two-year survival was 75% for Group I and 55% for Group II (P =
NS). To date 35 patients who had complete resection are alive, and free of
disease. We conclude that preoperative chemotherapy produces high response
and resectability rates in both stage IIIA and IIIB unresectable NSCLC;
radical resection using a conservative technique is possible in patients
who are otherwise unresectable; no local recurrence occurred after radical
resection; no significant differences were demonstrated between the two
protocols.
ARTICLES
Preoperative chemotherapy and immunochemotherapy for locally advanced stage IIIA and IIIB non small cell lung cancer. Preliminary results
Department of Thoracic Surgery, University of Rome La Sapienza, Policlinico Umberto I, Italy.
This article has been cited by other articles:
![]() |
S. J. Moschos, H. D. Edington, S. R. Land, U. N. Rao, D. Jukic, J. Shipe-Spotloe, and J. M. Kirkwood Neoadjuvant Treatment of Regional Stage IIIB Melanoma With High-Dose Interferon Alfa-2b Induces Objective Tumor Regression in Association With Modulation of Tumor Infiltrating Host Cellular Immune Responses J. Clin. Oncol., July 1, 2006; 24(19): 3164 - 3171. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sonobe, M. Nakagawa, M. Ichinose, N. Ikegami, M. Nagasawa, and T. Shindo Analysis of risk factors in bronchopleural fistula after pulmonary resection for primary lung cancer Eur. J. Cardiothorac. Surg., November 1, 2000; 18(5): 519 - 523. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Vansteenkiste, P. De Leyn, G. Deneffe, J. Menten, T. Lerut, and M. Demedts Present status of induction treatment in stage IIIA-N2 non-small cell lung cancer: a review Eur. J. Cardiothorac. Surg., January 1, 1998; 13(1): 1 - 12. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Rendina, F. Venuta, T. De Giacomo, I. Flaishman, P. Fazi, C. Ricci, Sponsor:, and V. W. Rusch SAFETY AND EFFICACY OF BRONCHOVASCULAR RECONSTRUCTION AFTER INDUCTION CHEMOTHERAPY FOR LUNG CANCER J. Thorac. Cardiovasc. Surg., November 1, 1997; 114(5): 830 - 837. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |